Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-cycloserine augmentation of accelerated TMS for treatment-resistant major depressive disorder
NL-OMON60741Phase 2Not yet recruiting
- Sponsor
- Maastricht University
- Start
- Aug 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of d-cycloserine in major depressive disorder (MDD), treatment-resistant depression (TRD), sponsored by Maastricht University. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
d-cycloserine
03
Conditions
major depressive disorder (MDD)treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NL-OMON60741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60741.